Key Highlights

  • Perrigo shares were up 11.87% in pre-market trading to $12.06, extending Tuesday's 0.94% close gain to $10.78.
  • Second-quarter adjusted EPS of $0.50 beat the consensus estimate of $0.34 by nearly 47%, with revenue of $1.02 billion topping the $1.01 billion estimate.
  • Net sales declined 3.2% year-over-year on a reported basis, reflecting the completed Dermacosmetics divestiture.
  • Infant Formula posted 23.1% growth during the quarter, offsetting lingering concerns about category softness elsewhere in the portfolio.
  • Management reaffirmed full-year 2026 adjusted EPS guidance of $2.00 to $2.30, with net income of $74.5 million for the quarter helping offset the prior year's net loss.

What's Behind the Rally

Perrigo (NYSE:PRGO) is a Dublin, Ireland-headquartered consumer self-care company founded in 1887, recognized as the largest store-brand over-the-counter provider in the United States and a top 10 OTC company in Europe. Operating through its Consumer Self-Care Americas and Consumer Self-Care International segments, the company develops, manufactures, and markets a broad portfolio of private-label and branded OTC health and wellness products, including well-known brands such as Mederma, Compeed, Opill, Nasonex, ellaOne, and Prevacid24HR.

Shares are surging in pre-market trading after the company delivered a strong second-quarter earnings beat, with adjusted EPS of $0.50 versus the $0.34 consensus estimate and revenue of $1.02 billion topping the $1.01 billion estimate. Investors are responding positively to signs of operational stabilization despite the 3.2% year-over-year decline in reported net sales, which primarily reflects the completed Dermacosmetics divestiture rather than underlying demand weakness.

Turnaround Signs Amid Category Headwinds

The results mark a notable turnaround from the prior-year quarter's net loss, with net income of $74.5 million this quarter helping offset lingering concerns about category softness and macroeconomic headwinds in the company's core Self Care segment. Under Interim President and CEO Albert Manzone, the company has been navigating a broader portfolio simplification strategy, including the completed sale of its branded Dermacosmetics business, aimed at sharpening focus on higher-margin, higher-growth categories.

Infant Formula, a segment that has weighed on results in recent quarters amid a broader strategic review, posted 23.1% growth during the period, providing an unexpected tailwind even as the long-term strategic direction for that business remains under evaluation.

Guidance and Outlook

Management reaffirmed its full-year 2026 adjusted EPS guidance of $2.00 to $2.30, a range that already reflects an expected temporary earnings drag of approximately $0.60 from 2026 plant underabsorption tied to lower 2025 production volumes. The company continues to target $60 million to $80 million in cost savings for the year as part of its ongoing simplification efforts.

Conclusion

Perrigo's earnings beat, paired with an unexpected rebound in Infant Formula and continued progress on portfolio simplification, suggests the company's turnaround efforts are beginning to show traction even as broader OTC category softness persists. With full-year guidance reaffirmed and net income back in positive territory, today's sharp pre-market advance points to renewed investor confidence that 2026 may prove to be the stabilization year management has been signaling.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.